Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma

Abstract

BackgroundDistinguishing urothelial carcinoma (UC) from prostate carcinoma (PC) is important due to potential therapeutic and prognostic implications. However, this can be a diagnostic challenge when there is limited tissue and in poorly differentiated tumors. We evaluated the diagnostic utility of a dual immunohistochemical stain comprising p63 and P501S (prostein), applied sequentially on a single slide and visualized by double chromogen reaction, in differentiating these two cancers. Thus far, there have been no previous studies assessing the diagnostic utility of p63 and P501S combined together as a dual immunostain in distinguishing between these two cancers.Methodsp63/P501S dual-color sequential immunohistochemical staining was performed on archival material from 132 patients with high-grade UC and 23 patients with PC, and evaluated for p63 (brown nuclear) and P501S (red cytoplasmic) expression. Both the staining intensity and percentage of positive tumor cells were assessed.Resultsp63 was positive in 119/132 of UC and negative in PC. P501S was positive in 22/23 of PC and negative in UC. The p63+/P501S- immunoprofile had 90% sensitivity and 100% specificity for UC. The p63-/P501S+ immunoprofile had 96% sensitivity and 100% specificity for PC.ConclusionOur results indicate that double sequential immunohistochemical staining with p63 and P501S is highly specific and can be a useful tool in distinguishing UC from PC especially when there is limited diagnostic tissue as it can be performed on a single slide.

The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis

“…Fourth, our meta-analysis is similarly with other works[20-22], while a more precise analysis should be conducted if individual data were available, which would allow for the adjustment by other covariates including age, sex, family history, environmental factors and lifestyle. Furthermore, other pathological type of urinary bladder cancer should be considered [23-25], which may be the source of publication. In addition, as in most meta-analyses, publication bias must be considered because only published studies were included in the meta-analysis.…”

Diagnostic and prognostic molecular biomarkers for prostate cancer

“…The prostate specificity has been confirmed independently and several groups have applied prostein IHC successfully to discriminate a prostatic cancer origin from tumours of the colon and bladder 107–112 . In particular, the common diagnostic problem of discriminating high‐grade prostate cancer from urothelial carcinoma can be tackled successfully with a combination of p63 and prostein 113 . The biological functions of prostein, which is androgen‐regulated and localized mainly to the Golgi apparatus of the cell, is still unclear.…”

Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience

“…It is mostly used as a diagnostic aid in breast, prostate, and salivary gland cancer because of its high sensitivity and specificity for mammary and salivary myoepithelial cells and prostatic basal cells [3,10-12]. It can be a useful tool in distinguishing urothélial carcinoma from prostatic carcinoma [13] and it can also be used as a prognosis factor as in adenoid cystic carcinoma [14]. …”